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Background. Hyperhomocysteinemia has been suggested to play a role in the NonValvular Atrial Fibrillation (NVAF)
pathogenesis. Polymorphisms in genes coding for homocysteine (Hcy) metabolism enzymes may be associated with
hyperhomocysteinemia and NVAF. Methodologies. 456 NVAF patients and 912 matched controls were genotyped by an
electronic microchip technology for C677T and A1298C MTHFR, A2756G MTR, and -786C/T eNOS gene polymorphisms. Hcy was
determined by an immunoassay method. Principal Findings. The genotype distribution of the four polymorphisms as well as
genotype combinations did not differ in patients and controls. Hcy was higher in patients than in controls (15.2, 95%CI 14.7–
15.7 vs 11.3, 95%CI 11.0–11.6 mmol/L; p,0.0001). In both populations, a genotype-phenotype association (p,0.0001) between
Hcy and C677T MTHFR polymorphism was observed; in controls a significant (p = 0.029) association between tHcy and2786C/T
eNOS polymorphism was also observed. At the multivariate analysis the NVAF risk significantly increased in the upper quartiles
of Hcy compared to the lowest: OR from 2.8 (1.68–4.54 95%CI) in Q2 to 12.9 (7.96–21.06 95%CI) in Q4. Conclusions. Our data
demonstrated the four polymorphisms, although able, at least in part, to affect Hcy, were not associated with an increased risk
of NVAF per se or in combination.
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INTRODUCTION
Nonvalvular atrial fibrillation (NVAF) is the most common
arrhythmia in clinical practice [1]. The molecular basis for the
development of structural remodeling of fibrillating human atria is
still a matter of debate and investigation. ‘‘Ex vivo’’ studies have
shown that NVAF is associated with enhanced activity of matrix
metalloproteinases (MMPs) [2] and tissue inhibitor of metallopro-
teinases (TIMPs) [3] at the human atrium level and in particular with
an increase in the expression of a disintegrin and metalloproteinases
(ADAM) 10 and ADAM15 [4]. In animal models and in vitro
human experiments it has been shown that MMPs are activated by
Hcy in both endothelial cells and arterial media [5–8]. We
demonstrated a significant association of elevated total homocysteine
(tHcy) levels with the presence of NVAF [9]. This datum strongly
suggested the possible role of hyperhomocysteinemia (HHcy) as new
factor involved in the pathogenesis of NVAF. Homocysteine is
a highly reactive, sulfur-containing amino acid formed as a by-
product of the essential amino acid methionine. It is estimated that 5
to 7% of the general population have mild to moderate HHcy. Mild
HHcy may result from both acquired (e.g. vitamin deficiencies) and
genetic influences [10,11]. Several genetic polymorphisms in gene
coding for enzymes involved in the Hcy metabolism are demon-
strated or suspected to be associated with HHcy [C677T and
A1298C in 5,10-methylenetetrahydrofolate reductase (MTHFR),
A2756G in methionine synthase (MTR)]. For C677T and A1298C
MTHFR polymorphisms, the variant allele is associated with
reduced enzyme activity in vitro [12,13]. For the A2756G MTR
polymorphism, functional data are limited and inconsistent [14].
Moreover, we previously demonstrated that 2786 T/C endothelial
nitric oxide synthase (eNOS) polymorphism, which is associated with
a reduction in the eNOS gene promoter activity, affects plasma Hcy
concentrations mildly but significantly and independently [15].
Aim of this study was to investigate whether C677T and
A1298C MTHFR, A2756G MTR and 2786 C/T eNOS gene
polymorphisms per se or in combination are associated with NVAF.
Our data demonstrated that the 4 polymorphisms, although able,
at least in part, to alter tHcy levels, were not associated, per se or in
combination, with an increased risk of NVAF.
MATERIALS AND METHODS
Subjects
We studied 456 consecutive chronic NVAF patients (271 men, 185
women) on oral anticoagulation, recruited from September 2002
to September 2005. All patients underwent an electrocardiogram,
transthoracic echocardiography, and carotid artery ultrasound
study. Exclusion criteria for patients were the presence of
hyperthyroidism or renal failure (serum creatinine.2.0 mg/dL).
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The control population comprised 912 matched (for age and
sex) healthy subjects (males 542, females 370) (blood donors and
partners or friends of the patients) from the same geographical
area. Exclusion criterion for the controls was a history of
cardiovascular disease or venous thromboembolic events evaluated
by a structured questionnaire to identify symptom-free controls
and to exclude subjects who were suspected of having any form of
vascular disease. No subject had abnormal liver or renal function.
Patients and controls gave their informed consent and the study
was approved by the Ethical Committee of the Careggi University
Hospital (Florence, Italy). Patients and controls were entirely
unrelated.
The presence of traditional cardiovascular risk factors and risk
factors for ischemic complications was assessed on the basis of
patients’ interview, echocardiography data and hospital records.
Dyslipidemia was defined according to the Third Report of the
National Cholesterol Education Program; hypertension in the
presence of blood pressure values above 130/80 mmHg and/or
an antihypertensive treatment and diabetes in agreement with the
criteria of the American Diabetes Association.
Blood collection and Hcy measurement
Venous blood was collected after an overnight fasting between 8 am
and 10 am. For Hcy measurement whole venous blood was collected
in tubes containing ethylenediaminotetracetate (EDTA) 0.17 mol/
L, immediately put in ice and centrifuged within 30 minutes at 4uC
(150006g for 15 min). The supernatant was stored in aliquots at
280uC until assay. The plasma levels of total Hcy were determined
by an immunoassay method (FPIA assay, IMX system, Abbott).
DNA Extraction
Genomic DNA was isolated from peripheral blood leukocytes by
using the Flexi Gene DNA kit (QIAGEN GmbH, Germany).
C677T MTHFR, A1298C MTHFR and A2756G MTR
polymorphisms detection by electronic microchip
We analyzed 3 DNA polymorphisms (C677T MTHFR, A1298C
MTHFR and A2756G MTR) by using the NanoChip Molecular
Biology Workstation and the NanoChip cartridge, a 10610 array
(100 pads). Briefly, in the following paragraph we reported the
protocols extensively described in a previous paper [16].
Probe design MTHFR and MTR gene sequences were
obtained fromGeneBank (www.ncbi.nlm.nih.gov, accession number
AY338232 and AL359259, respectively). For each polymorphism we
designed a set of probes consisting of a forward and a reverse
oligonucleotide for the polymerase chain reaction (PCR) amplifica-
tion, two reporter oligonucleotides (one, labeled with Cy3, specific
for the wild-type nucleotide, the other, labeled with Cy5, specific for
the mutant nucleotide), and one stabilizer oligonucleotide. All the
designed oligonucleotides are reported in Table 1.
Sample amplification To genotype the 3 polymorphisms, 3
DNA sequences were amplified by PCR. In Table 1 the annealing
temperature for each DNA fragment is reported.
Sample preparation The 3 amplicons of each subject were
pooled and desalted using the Nucleo Fast 96 well plates
(Macherey-Nagel). Samples were eluted in 55ml of deionized
water. Thirty ml of amplicon pools were mixed with 30 ml of
100 mmol/L histidine and transferred to a 96-well plate.
Addressing of amplicons on electronic chip The Loader
was programmed to electronically address each amplicon pool to
specific pads on the cartridge.
Hybridization, stripping procedures and data
analysis One set of stabilizer and reporter oligonucleotides at
a time was hybridized to the NanoChip cartridge. Reporter
oligonucleotides were mixed at 0.5 mmol/L each in high-salt
buffer (50 mmol/L sodium phosphate pH 7.4, and 500 mmol/L
NaCl) in combination with 1 mmol/L of stabilizer oligonucleotide.
After rinsing, the cartridge was placed in the NanoChip Reader
where a specific thermal stringency was applied. The specific
temperatures used for each polymorphism are reported in Table 1.
After each hybridization and scanning procedure, a stripping
procedure was performed to remove reporters, and to allow the
hybridization with another set of probes. The reporters were
stripped by rising temperature 15uC above the Tm of reporters.
In order to study all 3 polymorphisms, we performed 3
hybridization/stripping steps. The software of the System
directly assigned the genotype to each sample.
Table 1. PCR and hybridization oligonucleotide designs for electronic microchip analysis
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SNP Type of oligonucleotides Sequences Tm (uC) Ta (uC) Tb (uC)
MTHFR C677T Forward PCR 59biotinTGAAGGAGAAGGTGTCTGCGGGA39 63.6 64
Reverse PCR 59AGGACGGTGCGGTGAGAGTG39 62.5
Stabilizer 59CTCCCGCAGACACCTTCTCCTTCA39 63.9 36
Reporter WT 59Cy3TGATGAAATCGG39 33.3
Reporter MUT 59Cy5ATGATGAAATCGA39 33.7
MTHFR A1298C Forward PCR 59biotinCAAGGAGGAGCTGCTGAAGA39 57.7 64
Reverse PCR 59CCACTCCAGCATCACTCACT39 57.7
Stabilizer 59CTTCACTGGTCAGCTCCTCCCCCCAC39 67.8 41
Reporter WT 59Cy3-TCAAAGACACTTT39 34.1
Reporter MUT 59Cy5TCAAAGACACTTG39 35.5
MTR A2756G Forward PCR 59CATGGAAGAATATGAAGATATTAGAC39 50.9 57
Reverse PCR 59biotinGAACTAGAAGACAGAAATTCTCTA39 51.1
Stabilizer 59CCATTATGAGTCTCTCAAGGTAAGTGGTAGAAAC39 61.6 38
Reporter WT 59Cy3GATATTAGACAGGA39 33.9
Reporter MUT 59Cy5ATATTAGACAGGG39 32.1
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eNOS 2786T.C polymorphism detection
The eNOS 2786T.C polymorphism was analyzed by PCR with
restriction fragment length polymorphism analysis. PCR was
performed with the primers 59-GTGTACCCCACCTGCATT-
CT-39 and 59-CCCAGCAAGGATGTAGTGAC-39, and DNA
(100 ng) was amplified at an annealing temperature of 60uC. The
PCR product (306 bp) was digested with NaeI restriction enzyme
(Turbo Nae I; Promega) to obtain fragments of 225 and 81 bp.
Statistical analysis
Statistical analysis was performed using the 11.5 SPSS software.
Differences in characteristics between NVAF patients and controls
were determined by using the t-test or Chi-square test. Log-
transformed values for Hcy were used in the analyses, and back
transformed for data presentation. Unless otherwise indicated,
data are given as geometric means and 95% Confidence Interval
(CI). Adjusted Hcy mean values for C677T MTHFR, A1298C
MTHFR, A2756G MTR and 2786 C/T eNOS genotypes were
estimated from linear models adjusted for sex, age and creatinine.
For the risk of NVAF associated with Hcy levels, we classified the
data into quartiles based on the distribution of this parameter
among patients and controls (Q1:#9.7; Q2:9.8–12.1; Q3:12.2–
16.0; Q4:$16.1 mmol/L). Univariate logistic regression analysis
was used to describe the relation of Hcy and MTHFR, MTR and
eNOS polymorphisms with NVAF. To perform the multivariate
analyses, logistic regression analysis was used with NVAF as the
dependent variables and age, sex, traditional cardiovascular risk
factors, MTHFR, MTR and eNOS polymorphisms and Hcy as
the independent variables. Odds ratios (OR) were adjusted for the
potential confounding variables which were associated with NVAF
with a p value,0.20 in the univariate analysis. Variables that
resulted not to be associated with the outcome were removed from
the final most parsimonious regression model through a backward
selection algorithm. All OR are given with their 95% CI. A value
of p,0.05 was chosen as the cut-off level for statistical significance.
The Bonferroni correction was used for multiple testing by
multiplying the nominal p-value of each test by the number of tests
conducted.
RESULTS
The clinical and laboratory characteristics of patients and control
subjects are reported in Table 2.
Among the traditional risk factors, the prevalence of hyperten-
sion, smoking habit and diabetes was significantly higher in
patients than in controls (Table 2).
Table 2. Clinical and laboratory characteristics of patients and
control subjects
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Characteristic Patients (n = 456) Controls (n = 912)
Age (y) 75 (21–98) 75 (21–98) ns
Sex (M/F) 271/185 542/370 ns
Hypertension (%) 265 (58.1) 379 (41.6) ,0.0001
Diabetes mellitus (%) 50 (13.6) 37 (4.1) ,0.005
Dyslipidemia (%) 139 (30.5) 243 (26.6) 0.077
Smoking habit (%) 155 (34.0) 185 (20.3) ,0.0001
History of CAD (%) 58 (13.6) –
LVEF,50% (%) 156 (36.6) –
Age is expressed as median (range). Other data are expressed as n (%). CAD,
coronary artery disease; LVEF, left ventricular ejection fraction. History of CAD






























Table 3. Genotype distributions and tHcy plasma levels according to genotype in patients and controls
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gene Polymorphism Controls N (%) tHcy mmol/L Patients N (%) tHcy mmol/L
MTHFR C677T
CC 225 (24.7) 10.7 (10.2–11.2) 133 (29.2) 13.1 (12.4–13.8)
CT 479 (52.5) 10.7 (10.4–11.1) 222 (48.7) 15.4 (14.9–16.7)
TT 208 (22.8) 13.6 (12.9–14.3) 101 (22.1) 17.9 (16.8–19.1)
p for trend ,0.0001 ,0.0001
MTHFR A1298C
AA 423 (46.4) 11.9 (11.5–12.4) 224 (49.1) 15.9 (15.2–16.6)
AC 407 (44.6) 10.8 (10.4–11.2) 196 (43.0) 14.8 (14.1–15.5)
CC 82 (9.0) 11.0 (10.1–12.0) 36 (7.9) 13.2 (11.8–14.8)
p for trend ns ns
MTR A2756G
AA 628 (68.9) 11.4 (11.1–11.8) 319 (70.0) 15.1 (14.64–15.7)
AG 265 (29.1) 11.1 (10.6–11.6) 128 (28.0) 15.2 (14.3–16.7)
GG 19 (2.1) 11.7 (9.8–14.1) 9 (2.0) 17.4 (13.9–21.8)
p for trend ns ns
2786 C/T eNOS
TT 283 (31,0) 11.3 (10.7–12.1) 132 (29,0) 15.9 (14.7–17.1)
TC 432 (47,4) 11.6 (10.7–12.5) 239 (52,3) 15.6 (14.8–16.5)
CC 197 (21.6) 12.8 (12.1–13.5) 85 (18,7) 15.1 (14.2–16.5)
p for trend 0.029 ns
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Total Hcy plasma levels were significantly higher in NVAF
patients than in controls (geometric mean 15.2, 95% CI 14.7–15.7
vs 11.3, 95% CI 11.0–11.6 mmol/L; p,0.0001 adjusted for sex,
age and creatinine).
Table 3 shows C677T MTHFR, A1298C MTHFR, A2756G
MTR and 2786 C/T eNOS polymorphism genotype distributions
and tHcy levels according to genotypes in patients and controls.
The C677T MTHFR, A1298C MTHFR, A2756G MTR and
2786 C/T eNOS genotype distributions were in Hardy-Weinberg
equilibrium in patients and controls.
The genotype distributions of the 4 polymorphisms were not
different in NVAF patients in comparison to controls.
In patients and controls a significant genotype-phenotype
association (p,0.0001) between tHcy levels and C677T MTHFR
polymorphism was observed (Table 3 and Figure 1). A significant
genotype-phenotype association between tHcy levels and2786 C/T
eNOS polymorphism in controls (p= 0.029), but not in patients, was
also observed (Table 3 and Figure 1). No significant genotype-
phenotype association between tHcy levels and A1298CMTHFR or
A2756G MTR polymorphisms in controls were observed (Table 3),
whereas only a trend was found in patients (Table 3). In particular, in
patient group, subjects with 1298AA and 1298AC MTHFR and
2756GG MTR genotypes showed higher levels of tHcy (Table 3).
Both in patient and control subjects, the combined genotypes
677TT/1298AC, 677TT/1298CC and 677CT/1298CC were
not observed, indicating the linkage disequilibrium between these
two polymorphisms in our populations. The distributions of the
possible combinations of the two common polymorphisms of the
MTHFR gene were not different in NVAF patients in comparison
to controls (Table 4). As concerns tHcy, it was significantly higher in
677TT/1298AA combination with respect to all the other possible
combinations both in patients and controls (p,0.001 and p,0.0001,
respectively). Moreover, in patient group, a statistical difference in
tHcy levels among 677CT/1298AC and 677CC/1298AC (p=
0.044) and 677CC/1298AA (p=0.005), and between 677CT/
1298AA and 677CC/1298AA (p=0.024) was observed.
The analysis of the distribution of all the possible combination
among C677T and A1298C MTHFR, A2756G MTR and 2786
C/T eNOS genotypes between patients and controls did not
showed significant differences. The analysis of the effect of the
combinations of all the 4 studied polymorphisms demonstrated
that the A2756G MTR and 2786 C/T eNOS polymorphisms
also did not interact with the C677T MTHFR polymorphism, in
patients and controls, in influencing tHcy levels (data not shown).
At the multiple analysis (adjusted for sex, age, creatinine levels,
hypertension, diabetes, dyslipidemia, smoking habitus, history of
CAD, polymorphisms), the risk of NVAF significantly increased in
the Q2, Q3 and Q4 of Hcy with respect to Q1: with an OR
increasing from 2.8 (1.68–4.54 95% CI) in Q2 to 12.9 (7.96–21.06
95% CI) in Q4 (Table 5). In spite of the influence of the C677T
MTHFR polymorphism on Hcy levels, this polymorphism was not
associated with the risk of NVAF (Table 5).
Figure 1. tHcy plasma levels according to C677T MTHFR genotypes (Figure 1A) and 2786 C/T eNOS genotypes (Figure 1B) in patients and
controls.
doi:10.1371/journal.pone.0000495.g001
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DISCUSSION
In the present study we have evaluated the role of 4 polymorphisms
known or suspected to influence Hcy plasma levels in determining
susceptibility to NVAF. At this purpose we investigated a large
population of consecutive NVAF patients. Our data demonstrated
that the 4 polymorphisms (C677T and A1298C MTHFR, A2756G
MTR and2786 C/T eNOS polymorphisms), although able, at least
in part, to alter tHcy levels, were not associated, per se or in
combination, with an increased risk of NVAF.
Recently our group demonstrated a significant association
between elevated Hcy levels and the presence of NVAF, suggesting
a role for HHcy as new factor involved in the pathogenesis of atrial
fibrillation [9]. In that study we did not find an association
between C677T MTHFR polymorphism per se and NVAF [9], but
those results were not conclusive, because the number of patients
examined was not sufficient to definitively exclude this hypothesis.
Moreover, we did not test the possibility that the C677T MTHFR
polymorphism could represent a risk factor for NVAF by interacting
with other polymorphisms involved in the Hcy metabolism.
Therefore, we studied 4 polymorphisms, three in genes directly
involved in Hcy metabolism (C677T and A1298C MTHFR and
A2756G MTR) and one in another gene indirectly involved as
determinant of Hcy levels (2786 C/T eNOS).
In vitro data showed that C677T and A1298C MTHFR
polymorphisms are associated with a reduced enzyme activity
[12,13]. Moreover, several in vivo studies demonstrated an
association between C677T MTHFR polymorphism and in-
creased tHcy plasma levels in healthy subjects and patients
affected by a number of cardiovascular diseases, especially in
subjects with low folate levels [17–19].
Limited and inconsistent data on the role of A1298C MTHFR
and in particular A2756G MTR polymorphism as determinant of
tHcy plasma levels are available. Recent data from our group
demonstrated on a large population of young healthy subjects that
2786 T/C eNOS polymorphism is a mild but independent
determinant of tHcy levels [15].
In the present study, as expected, a significant genotype-
phenotype association between tHcy levels and C677T MTHFR
polymorphism in NVAF patients and controls was observed. A
significant genotype-phenotype association between tHcy levels
and 2786 C/T eNOS polymorphism in these older control
subjects was also confirmed, but not observed in NVAF patients. It
has to be underlined that it is the second report showing the
genotype-phenotype association between 2786 C/T eNOS
polymorphism and tHcy levels in a large healthy population
[previous work [15]:1287 healthy subjects, median age= 60 years,
range = 20–78 years; present work: 972 healthy subjects, median
age = 75 years, range= 21–98 years].
As concerns the other two polymorphisms, although higher
tHcy levels could be observed in NVAF patients carrying the
1298AA MTHFR and the 2756GG MTR genotypes, a significant
genotype-phenotype association was not demonstrated in both
patients and controls.
In spite of these observations, the evaluation of the possible role
of genotype combinations in determining tHcy levels did not
identify any interactions among the 4 studied polymorphisms.
As concerns the two MTHFR polymorphisms investigated, the
distribution of the combined genotypes suggests that the A1298C
MTHFR polymorphism is genetically linked with the C677T
MTHFR polymorphism. Previous studies [13,20–22] indicated
that the 677T and 1298C alleles do not or very rarely exist in cis
(on the same chromosome), suggesting that these two polymorph-
isms arose independently in separate chromosomes and no
recombination had occurred due to short physical distance
(2.1 kb) between them. An alternative explanation is that there
was a selection against cis because of a severely adverse phenotype.
The latest hypothesis was not confirmed through an in vitro study
by site-directed mutagenesis, which demonstrated cis did not
confer a severe phenotype [23].
These data also explain at least in part the observed higher tHcy
levels in 1298AA MTHFR subjects with respect to the other
1298AC and CC genotypes. In fact, due to the linkage
disequilibrium, all the 677TT MTHFR subjects belong to the
group of subjects with the 1298AA genotype.
Data of the present study, conducted in a different and larger
NVAF population with respect to the previous published work on
NVAF [9], confirmed the observed strong association between
Table 4. Genotype combination distributions and tHcy plasma levels according to genotype combination in patients and controls
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
MTHFR C677T MTHFR A1298C Controls N (%) tHcy mmol/L Patients N (%) tHcy mmol/L
TT AA 208 (22.8) 13.5 (12.9–14.3) 102 (22.3) 17.9 (16.8–19.1)
CT AC 302 (33.1) 10.8 (10.3–11.2) 132 (28.9) 15.5 (14.7–16.4)
CT AA 177 (19.4) 10.7 (10.1–11.4) 90 (19.7) 15.2 (14.2–16.3)
CC CC 82 (9.0) 11.0 (10.1–11.9) 36 (7.9) 13.2 (11.9–14.7)
CC AC 105 (11.5) 10.8 (10.0–11.6) 63 (13.8) 13.4 (12.3–14.5)





















Table 5. Odds ratios for NVAF according to Hcy quartiles,
C677T MTHFR and 2786 C/T eNOS polymorphism and other
traditional factors known influenced Hcy plasma levels
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Multivariate analysis OR (95% CI)p*
Hcy
Q1 1
Q2 2.8 (1.68–4.54) ,0.0001
Q3 6.6 (4.09–10.67) ,0.0001
Q4 12.9 (7.96–21.06) ,0.0001
C677T MTHFR 0.8 (0.56–1.12) 0.184
2786 C/T eNOS 0.9 (0.68–1.43) 0.945
Hypertension 1.9 (1.46–2.57) ,0.0001
Dyslipidemia 1.4 (1.00–1.86) 0.048
Smoking habit 2.4 (1.68–3.32) ,0.0001
Diabetes mellitus 3.23 (2.56–7.56) ,0.0001
*Adjusted for age, sex, traditional cardiovascular risk factors, polymorphisms
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elevated tHcy levels and the presence of NVAF. Interestingly, at the
multivariate analysis, the risk of NVAF significantly increased in the
three upper quartiles of Hcy with respect to the lowest quartile: with
anOR increasing from 2.8 to 12.9. This datum suggests a gradient in
which at the increase of Hcy levels corresponds a proportional
increase in the estimated risk of NVAF.
Even if associations do not prove causality, this evidence
together with that of the previous work [9] (on a total number of
766 patients: 310 previous work and 456 present work) indicates
a possible independent role of elevated Hcy levels as a risk factor
for NVAF, in a model adjusted for age, sex, and the traditional risk
factors for NVAF.
Atrial fibrillation usually occurs in the context of an atrial
substrate produced by alterations in atrial tissue properties referred
to as remodeling. Increased levels of Hcy might be implicated in
the remodeling of the extracellular matrix of the cardiac wall by
direct or indirect action. Studies in animal models demonstrated
that HHcy could induce marked remodeling of the extracellular
matrix by inducing elastolysis through the activation of MMPs
[5,7,8]. In addition, Hcy may directly affect extracellular matrix
components by interfering with intra- and/or inter-molecular
disulfide bonds through disulfide exchange, or binding to free
sulphydril groups [24,25].
We should consider the hypothesis that high Hcy levels are
either a consequence of NVAF or just a marker of other diseases
and/or deficiencies of B vitamins, which can, by themselves, be
responsible for abnormalities that increase the risk of NVAF
independently of Hcy levels.
Importantly, the association between Hcy and NVAF does not
stem from the presence of coronary artery disease as it persists at
the multivariate analysis adjusted also for history of coronary
artery disease. As far as vitamin status is concerned, a limitation of
this study is the lack of information about this issue.
Due to the high number of genes that could modulate plasma
Hcy levels [26], we cannot role out the need to evaluate the
interaction among a higher number of polymorphisms in the same
and different genes. Together with the observation that increased
tHcy levels associated with the increased risk of NVAF could be
determined by non-genetic factors, we should take into account
that the advantage due to polymorphisms in term of protection
against cancers [14,27,28] in this elder population could, at least in
part, mask the contribution of these polymorphisms to the risk for
NVAF that is so strong for the increased tHcy levels.
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